The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Treatments for Scleroderma with Gastrointestinal Involvement Address Symptoms

Treatments for Scleroderma with Gastrointestinal Involvement Address Symptoms

June 13, 2016 • By Thomas R. Collins

  • Tweet
  • Email
Print-Friendly Version / Save PDF
Nine out of 10 scleroderma cases include clinical signs of GI involvement.

Nine out of 10 scleroderma cases include clinical signs of GI involvement.
Tashatuvango/shutterstock.com

CHICAGO—Nine out of 10 scleroderma cases include clinical signs of gastrointestinal (GI) involvement, with severe involvement associated with high mortality rates, but the pathology of this is not very well understood, a GI expert said at the ACR’s State-of-the-Art Clinical Symposium.

You Might Also Like
  • ACR/ARHP Annual Meeting 2012: Physicians Find Treatment Options Limited for Scleroderma Bowel Disease
  • Markers for Severe Gastrointestinal Dysmotility in Systemic Sclerosis
  • Pain Perspective in Scleroderma
Explore This Issue
June 2016
Also By This Author
  • New Research into Rheumatoid Arthritis, Gout Includes Updates on Methotrexate, Biologics, Ultrasound

That has left clinicians with a slate of treatments—anti-reflux, antimicrobials and prokinetics—that address only the symptoms, some with more effectiveness than others, and some with more side effects, said John O. Clarke, MD, clinical director of the Johns Hopkins Center for Neurogastroenterology.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

In scleroderma, the GI tract is the most commonly involved system, other than the skin, with the esophagus most commonly affected. Typical symptoms in scleroderma patients range widely, including dysphagia, heartburn, regurgitation and nausea, abdominal pain, diarrhea, constipation and incontinence. Other rheumatic diseases can also have varied involvement, but it tends to be less widespread, Dr. Clarke said.

GI involvement is the presenting feature in just 10% of scleroderma cases, but autopsies have found involvement in 94%. Severe involvement has been found in only about 8% of cases, but just 15% of those patients survive more than nine years, and GI involvement is the third-leading cause of mortality in scleroderma.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

A four-stage process of GI involvement has been proposed, with an early vascular lesion followed by neural dysfunction, and then smooth muscle atrophy followed by smooth muscle fibrosis. But autopsies have found that smooth muscle atrophy is found more commonly in these patients than fibrosis, refuting the theory.

Dr. Clarke

Dr. Clarke

“This is controversial,” Dr. Clarke said. “The bottom line is that it’s not entirely certain that this four-stage [process] is correct.”

Dysmotility is the main manifestation, with poor propulsion of food through the gut.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

“I do think that dysmotility is so frequent in these patients that, if you see someone who comes in with characteristic symptoms, it’s very reasonable to treat them up front,” Dr. Clarke said.

Treatments

The main lifestyle changes for reflux are stopping smoking, avoiding alcohol, elevating the head at least two inches when sleeping and not eating within three hours of sleeping. Avoiding certain foods can have different effects in different people, Dr. Clarke said.

The most effective medical treatment is proton-pump inhibitors, which take longer to start working but are longer acting. Prokinetics that strengthen the lower esophageal sphincter are another option, but only metoclopramide is FDA approved. Other treatments, including the 5HT1-receptor agonist buspirone, are emerging, Dr. Clarke said.

Pages: 1 2 3 | Single Page

Filed Under: Conditions, Scleroderma Tagged With: 2016 State-of-the-Art Clinical Symposium, gastrointestinal, patient care, Research, Scleroderma, TreatmentIssue: June 2016

You Might Also Like:
  • ACR/ARHP Annual Meeting 2012: Physicians Find Treatment Options Limited for Scleroderma Bowel Disease
  • Markers for Severe Gastrointestinal Dysmotility in Systemic Sclerosis
  • Pain Perspective in Scleroderma
  • Studies Show Promise for Scleroderma Therapy and Prediction of Progressing Disease

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)